Table 1.
TNBC subtyping predictions for TCGA primary breast tumors
| TNBC Subtypea | # Samples (Percentage) | Median DFS (Months)b | Median OS (Months)b |
|---|---|---|---|
| BL1 | 27 (17%) | 20.1 | 21.1 |
| BL2 | 12 (7%) | 12.5 | 8.4 |
| IM | 30 (18%) | 22.7 | 24.8 |
| M | 39 (24%) | 9.1 | 9.5 |
| MSL | 10 (6%) | 13.9 | 20.9 |
| LAR | 14 (9%) | 4.4 | 5.7 |
| UNC | 31 (19%) | 22.0 | 24.9 |
|
| |||
| All TNBC | 163 (100%) | 11.8 | 15.2 |
Abbreviations: DFS, disease free survival; OS, overall survival.
a
TNBC subtype predictions for the TCGA primary tumors were made using RSEM genes normalized (upper quartile count = 1,000) RNA-seq abundance estimates (20130606 Firehose BRCA stddata run). TNBC cases were identified as previously described (8). Samples were filtered on ER, PR, and HER2 mRNA expression to identify TNBC tumors and outliers were removed after principal component analysis. The TNBCtype tool (10) was used to make TNBC subtype predictions for the 163 TNBC samples.
b
Survival data for TCGA TNBC cases was obtained from the cBioPortal (www.cbioportal.org) on 12-19-2013.